You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Severe Hemophilia A

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hemophilia A, Hemophilia B Trial (SerpinPC)

Not yet recruiting
  • Hemophilia A
  • Hemophilia B
  • (no location specified)
Mar 16, 2023

Hemophilia B Without Inhibitor Trial (Low dose KL001, Middle dose KL001, High dose KL001)

Not yet recruiting
  • Hemophilia B Without Inhibitor
  • Low dose KL001
  • +2 more
  • (no location specified)
Nov 5, 2023

Severe Hemophilia A Without Inhibitor, Joint Bleed Trial in Bangkok ("Emicizumab", "HEMLIBRA®")

Recruiting
  • Severe Hemophilia A Without Inhibitor
  • Joint Bleed
  • "Emicizumab", "HEMLIBRA®"
  • Bangkok, Thailand
    King Chulalongkorn Memorial hospital
Nov 25, 2023

Hemophilia B Without Inhibitor Trial (Low dose KL001, Middle dose KL001, High dose KL001)

Not yet recruiting
  • Hemophilia B Without Inhibitor
  • Low dose KL001
  • +2 more
  • (no location specified)
Nov 5, 2023

Dynamics of Anti-factor VIII Antibody Signature During Treatment

Not yet recruiting
  • Severe Hemophilia A
  • +2 more
  • no interventions
  • (no location specified)
Apr 4, 2023

Bleeding Rates Among Severe Hemophilia A on Emicizumab

Not yet recruiting
  • Hemophilia A
  • Newark, New Jersey
    Newark Beth Israel Medical Center
Oct 26, 2023

Hemophilia A Trial in Roma (SenseWear armband device)

Completed
  • Hemophilia A
  • SenseWear armband device
  • Roma, Italy
    FPG
Mar 1, 2023

Hemophilia A Trial (Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin

Not yet recruiting
  • Hemophilia A
  • Fitusiran (SAR439774)
  • +3 more
  • (no location specified)
Nov 17, 2023

Hemophilia B Trial (CSL222 (AAV5-hFIXco-Padua))

Not yet recruiting
  • Hemophilia B
  • CSL222 (AAV5-hFIXco-Padua)
  • (no location specified)
Aug 14, 2023

Hemophilia A Trial in Abidjan (Prophylaxis with Emicizumab)

Completed
  • Hemophilia A
  • Prophylaxis with Emicizumab
  • Abidjan, Côte D'Ivoire
    CHU de Yopougon
Oct 24, 2022

Severe Hemophilia A Subjects Who Received BMN 270 inPrior

Enrolling by invitation
  • Hemophilia A
    • London, United Kingdom
      Royal London Hospital, Barts and the London Hemophilia Center
    Mar 13, 2023

    Hemophilia A Trial in Little Rock (ASC618)

    Recruiting
    • Hemophilia A
    • ASC618
    • Little Rock, Arkansas
      Arkansas Children's Hospital
    Jan 30, 2023

    Hemophilia A, Hemophilia B Trial in Korea, Republic of, South Africa, Taiwan (marstacimab)

    Recruiting
    • Hemophilia A
    • Hemophilia B
    • Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
    • +3 more
    Jan 18, 2023

    Hemophilia B Trial in Beijing (Sodium valproate extended-release tablets)

    Recruiting
    • Hemophilia B
    • Sodium valproate extended-release tablets
    • Beijing, China
      PLA General Hospital
    Jun 17, 2023

    Severe Hemophilia A Trial in China (FRSW107)

    Not yet recruiting
    • Severe Hemophilia A
    • Baoding, China
    • +13 more
    Nov 16, 2023

    Severe Hemophilia A Trial (Nuwiq)

    Not yet recruiting
    • Severe Hemophilia A
    • (no location specified)
    Jul 3, 2023

    A Prospective and Retrospective Interventional Study on

    Recruiting
    • Severe Hemophilia A Without Inhibitor
    • serum biomarker.
    • Taipei, Neihu Dist., Taiwan
      Tri-Service General Hospital Hemophilia Care Center
    Aug 10, 2023

    Hemophilia Trial in Orange (Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate

    Recruiting
    • Hemophilia
    • Orange, California
      Center for Inherited Blood Disorders (CIBD)-Site Number:8400012
    Feb 2, 2023

    Hemophilia Trial in Bangkok (combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided

    Completed
    • Hemophilia
    • combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
    • pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
    • Bangkok, Thailand
      King Chulalongkorn Memorial Hospital
    Feb 5, 2023

    Severe Hemophilia A Trial in Poznan, Krakow (Alphanate SD/HT)

    Completed
    Has Results
    • Severe Hemophilia A
    • Alphanate SD/HT
    • Poznan, Szkolna, Poland
    • +1 more
    May 16, 2022

    Hemophilia Trial (BFRT, Control)

    Not yet recruiting
    • Hemophilia
    • BFRT
    • Control
    • (no location specified)
    Dec 14, 2022

    Severe Hemophilia A Trial in Iran, Islamic Republic of (Factor VIII, recombinant human with Fc fusion (rFVIII-Fc))

    Completed
    • Severe Hemophilia A
    • Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)
    • Isfahan, Iran, Islamic Republic of
    • +4 more
    Nov 13, 2023

    In Vitro Correction of Thrombin Generation by Concizumab for

    Recruiting
    • Hemophilia
    • thrombin generation measurement
    • Saint-Etienne, France
      CHU Saint-Etienne
    Dec 13, 2022

    Severe Hemophilia Non-Interventional Study

    Not yet recruiting
    • Hemophilia A
    • Hemophilia B
    • No Intervention
    • Rzeszów, Podkarpackie, Poland
    • +2 more
    Dec 8, 2022

    Hemophilia B Trial in Denmark, Germany, Netherlands (AAV5-hFIX)

    Completed
    Has Results
    • Hemophilia B
    • AAV5-hFIX
    • Copenhagen, Denmark
    • +6 more
    Jun 1, 2022